The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP

Simple item page
dc.contributor.authorDouros, Jonathan D.
dc.contributor.authorFlak, Jonathan N.
dc.contributor.authorKnerr, Patrick J.
dc.contributor.departmentPharmacology and Toxicology, School of Medicine
dc.date.accessioned2025-03-25T11:17:11Z
dc.date.available2025-03-25T11:17:11Z
dc.date.issued2025-02-03
dc.eprint.versionFinal published version
dc.identifier.citationDouros JD, Flak JN, Knerr PJ. The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP. Front Endocrinol (Lausanne). 2025;16:1530985. Published 2025 Feb 3. doi:10.3389/fendo.2025.1530985
dc.identifier.urihttps://hdl.handle.net/1805/46567
dc.language.isoen_US
dc.publisherFrontiers Media
dc.relation.isversionof10.3389/fendo.2025.1530985
dc.relation.journalFrontiers in Endocrinology
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourcePMC
dc.subjectGIP - glucose-dependent insulinotropic peptide
dc.subjectGLP-1 - glucagon-like peptide-1
dc.subjectIncretin
dc.subjectObesity
dc.subjectPharmacology
dc.titleThe agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Douros2025Agony-CCBY.pdf
Size:
2.61 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Pharmacology and Toxicology Works